The US FDA has licensed GeneGo Inc's MetaCore for OMIC's research and reviewing of genomics data. GeneGo and the FDA will also integrate MetaCore with ArrayTrack and make it available for FDA researchers.

According to a company release, the MetaCore platform allows scientists to concurrently visualise, map and network multiple types of data including gene expression, SiRNAi, proteomic, metabolomic, SAGE and SNP data, both from pre-clinical discovery and clinical studies. ArrayTrack provides an integrated solution for managing, analysing, and interpreting microarray gene expression data.

"High throughput (HT) experimentation is increasingly important for life science research, and HT data is now included in many new drug applications submissions. The analysis of such complex datasets requires novel systems biology tools, such as MetaCore. One important issue in FDA submissions is compatibility and cross-referencing of multiple types of pre-clinical and clinical data, which are collected at different times by different research groups. MetaCore offers both a functional framework and analytical engine for this," said Dr Tatiana Nikolskaya, founder and CSO of GeneGo Inc.

GeneGo has assembled the world largest manually curated database of human biology and medicinal chemistry, which includes genes, proteins, natural ligands, metabolites, drugs and diseases from millions of literature findings.